IMMX Earnings & Financial Statements
Immix Biopharma, Inc.
$8.79
+$0.28(+3.23%)
40
Overall
60
Value
27
Tech
34
Quality
Market Cap
$705.50M
Volume
576.20K
52W Range
$2.31 - $15.10
Target Price
$24.57
IMMX earnings and financial statements: Immix Biopharma, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
IMMX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$29.96M | -$22.67M | -$16.14M | -$8.22M | -$1.35M |
| EBITDA | -$29.00M | -$21.54M | -$15.56M | -$8.22M | -$24.14M |
| Net income | -$29.40M | -$21.61M | -$15.43M | -$8.23M | -$24.38M |
| EPS (diluted) | $-0.89 | $-0.76 | $-0.89 | $-0.59 | $-6.64 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $104.84M | $22.95M | $19.93M | $14.91M | $18.19M |
| Total liabilities | $11.04M | $9.70M | $3.72M | $1.75M | $202.0K |
| Shareholders’ equity | $93.76M | $13.25M | $16.41M | $13.16M | $17.99M |
| Cash and equivalents | $93.93M | $17.68M | $17.51M | $13.44M | $17.64M |
| Long-term debt | $933.6K | $1.01M | - | - | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$23.93M | -$14.60M | -$11.37M | -$7.41M | -$1.59M |
| Capital expenditure | -$732.9K | -$1.18M | -$52.1K | - | -$802.00 |
| Free cash flow | -$24.66M | -$15.77M | -$11.42M | -$7.41M | -$1.59M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IMMX | $8.79 | +3.2% | 576.20K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |